PALYNZIQ

This brand name is authorized in Austria, Estonia, France, Croatia, Ireland, Italy, Japan, Lithuania, Poland, United States

Active ingredients

The drug PALYNZIQ contains one active pharmaceutical ingredient (API):

1 Pegvaliase UNII N6UAH27EUV - PEGVALIASE

Pegvaliase is a PEGylated recombinant phenylalanine ammonia lyase enzyme that converts phenylalanine to ammonia and trans-cinnamic acid that are primarily eliminated by liver metabolism. Read about Pegvaliase

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
PALYNZIQ Solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/PLR
PALYNZIQ Solution for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
A16AB19		A Alimentary tract and metabolism → A16 Other alimentary tract and metabolism products → A16A Other alimentary tract and metabolism products → A16AB Enzymes
Discover more medicines within A16AB19

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1795989, 1795990, 1796003, 1796070
Country: FR	Base de données publique des médicaments	Identifier(s): 61661596, 65887105, 67940880
Country: IT	Agenzia del Farmaco	Identifier(s): 047940010, 047940022, 047940034, 047940046
Country: JP	医薬品医療機器総合機構	Identifier(s): 39994E9G1029, 39994E9G2025, 39994E9G3021
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1087709, 1087710, 1087711, 1087712
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100421218, 100421224, 100421230
Country: US	FDA, National Drug Code	Identifier(s): 68135-058, 68135-673, 68135-756